Paul M Sondel Selected Research

dinutuximab

12/2022	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
1/2022	Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.
1/2021	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
1/2020	Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma.
1/2020	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
1/2018	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
1/2018	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
1/2017	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
1/2017	Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
1/2016	Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul M Sondel Research Topics

Disease

88	Neoplasms (Cancer) 09/2022 - 09/2002
46	Neuroblastoma 12/2022 - 01/2004
19	Melanoma (Melanoma, Malignant) 01/2022 - 01/2005
7	Hypotension (Low Blood Pressure) 12/2022 - 03/2006
6	Hypersensitivity (Allergy) 12/2022 - 07/2006
6	Experimental Melanoma 01/2021 - 05/2005
6	Pain (Aches) 12/2018 - 07/2006
5	Necrosis 01/2016 - 06/2006
4	Fever (Fevers) 12/2022 - 01/2009
3	Breast Neoplasms (Breast Cancer) 01/2021 - 08/2004
3	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2004
3	Residual Neoplasm 10/2019 - 07/2009
3	Capillary Leak Syndrome 01/2018 - 01/2009
3	Renal Cell Carcinoma (Grawitz Tumor) 05/2017 - 09/2002
2	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 01/2021
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2021
2	Lymphoma (Lymphomas) 01/2021 - 02/2009
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2019 - 01/2017
2	Hypoxia (Hypoxemia) 01/2017 - 11/2010
2	Lymphocytosis 12/2012 - 03/2006
2	Sarcoma (Soft Tissue Sarcoma) 08/2008 - 07/2006
2	Adenocarcinoma 08/2004 - 09/2002
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022
1	Sudden Death 01/2022
1	Disease Progression 01/2020
1	COVID-19 01/2020

Drug/Important Bio-Agent (IBA)

30	Interleukin-2 (IL2)IBA 12/2022 - 01/2004
28	Monoclonal AntibodiesIBA 01/2022 - 06/2003
19	lorukafusp alfaIBA 01/2021 - 01/2004
17	CytokinesIBA 01/2022 - 06/2003
14	dinutuximabIBA 12/2022 - 07/2006
13	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 01/2007
11	AntibodiesIBA 01/2022 - 07/2006
8	LigandsIBA 12/2019 - 12/2010
6	Interleukin-12 (IL 12)IBA 09/2022 - 09/2002
6	Proteins (Proteins, Gene)FDA Link 10/2020 - 06/2003
6	Isotretinoin (Accutane)FDA LinkGeneric 10/2019 - 09/2010
6	AntigensIBA 01/2016 - 01/2010
5	VaccinesIBA 09/2022 - 01/2010
5	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
5	Immunoglobulin G (IgG)IBA 01/2020 - 01/2016
4	Radioisotopes (Radionuclides)IBA 01/2021 - 12/2007
4	OligodeoxyribonucleotidesIBA 01/2021 - 03/2007
4	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 01/2010
4	Neoplasm Antigens (Tumor Antigens)IBA 05/2017 - 12/2008
4	KIR ReceptorsIBA 12/2016 - 12/2010
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2012 - 06/2006
3	RNA (Ribonucleic Acid)IBA 01/2022 - 11/2018
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2017
3	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 01/2017
3	Complement System Proteins (Complement)IBA 01/2020 - 07/2014
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2017
3	GlycolipidsIBA 01/2016 - 01/2010
3	Interleukin-2 Receptors (IL 2 Receptor)IBA 12/2011 - 03/2006
3	DNA (Deoxyribonucleic Acid)IBA 11/2011 - 09/2002
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2007 - 01/2006
2	Fc Receptors (Fc Receptor)IBA 01/2022 - 01/2012
2	Rituximab (Mabthera)FDA Link 12/2019 - 01/2017
2	HLA-Bw4 antigenIBA 12/2019 - 01/2017
2	Therapeutic UsesIBA 01/2019 - 01/2018
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2018 - 11/2017
2	Interleukin-15 (Interleukin 15)IBA 01/2018 - 01/2016
2	IgG Receptors (Fc gamma RI)IBA 05/2017 - 01/2016
2	FenretinideIBA 11/2013 - 11/2011
2	LipidsIBA 11/2013 - 09/2002
2	Interferon-gamma (Interferon, gamma)IBA 10/2012 - 01/2004
2	LipopolysaccharidesIBA 10/2012 - 06/2006
2	tucotuzumab celmoleukinIBA 12/2011 - 08/2009
2	ResveratrolIBA 11/2011 - 05/2011
2	Dopamine (Intropin)FDA LinkGeneric 11/2010 - 03/2006
2	Transaminases (Aminotransferases)IBA 11/2010 - 01/2009
1	carboxyaminoimidazole ribotide (CAIR)IBA 01/2022
1	Macrophage Colony-Stimulating FactorIBA 01/2022
1	AlginatesIBA 01/2022
1	HydrogelsIBA 01/2022
1	Keratin-17 (Keratin 17)IBA 01/2022
1	pembrolizumabIBA 01/2022
1	pexidartinibIBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	NAD (NADH)IBA 01/2021
1	bempegaldesleukinIBA 01/2021
1	Flavin-Adenine Dinucleotide (FAD)IBA 01/2021
1	Cancer VaccinesIBA 01/2021
1	Tumor Biomarkers (Tumor Markers)IBA 01/2020
1	Neoplasm AntibodiesIBA 01/2020

Therapy/Procedure

53	Immunotherapy 12/2022 - 09/2002
45	Therapeutics 12/2022 - 01/2004
10	Radiotherapy 01/2022 - 01/2012
8	Drug Therapy (Chemotherapy) 11/2017 - 06/2009
5	Ligation 08/2012 - 05/2005
3	Injections 01/2021 - 01/2010
2	Induction Chemotherapy 01/2022 - 11/2019
2	Precision Medicine 01/2021 - 01/2019
2	Intraperitoneal Injections 01/2013 - 05/2005
2	Stem Cell Transplantation 01/2012 - 09/2010
1	Combination Drug Therapy (Combination Chemotherapy) 01/2022
1	Neoadjuvant Therapy 01/2022
1	Intravenous Injections 10/2020
1	Blood Component Removal (Apheresis) 01/2020